Your browser is no longer supported. Please, upgrade your browser.
ImmunoGen, Inc.
Index- P/E- EPS (ttm)-0.27 Insider Own0.40% Shs Outstand198.84M Perf Week-2.79%
Market Cap1.12B Forward P/E- EPS next Y-0.81 Insider Trans0.00% Shs Float180.58M Perf Month-14.42%
Income-49.30M PEG- EPS next Q-0.18 Inst Own92.90% Short Float12.25% Perf Quarter-28.37%
Sales134.70M P/S8.31 EPS this Y64.10% Inst Trans0.66% Short Ratio11.53 Perf Half Y-24.39%
Book/sh0.47 P/B11.87 EPS next Y-3.80% ROA-16.20% Target Price- Perf Year26.53%
Cash/sh1.41 P/C3.96 EPS next 5Y- ROE-169.70% 52W Range3.38 - 10.88 Perf YTD-13.49%
Dividend- P/FCF- EPS past 5Y31.50% ROI-24.40% 52W High-48.71% Beta1.33
Dividend %- Quick Ratio2.40 Sales past 5Y17.10% Gross Margin- 52W Low65.09% ATR0.24
Employees79 Current Ratio2.40 Sales Q/Q18.00% Oper. Margin-20.40% RSI (14)32.60 Volatility3.81% 3.83%
OptionableYes Debt/Eq0.02 EPS Q/Q1.70% Profit Margin-36.60% Rel Volume0.43 Prev Close5.60
ShortableYes LT Debt/Eq0.00 EarningsJul 30 BMO Payout- Avg Volume1.92M Price5.58
Recom2.10 SMA20-10.07% SMA50-11.59% SMA200-19.67% Volume816,100 Change-0.36%
Oct-26-20Resumed H.C. Wainwright Buy $11
Oct-02-20Upgrade Guggenheim Neutral → Buy $14
Sep-29-20Resumed JP Morgan Neutral
Dec-17-19Reiterated H.C. Wainwright Buy $5 → $9
Aug-13-19Reiterated H.C. Wainwright Buy $4 → $5
May-15-19Downgrade Guggenheim Buy → Neutral
May-06-19Upgrade H.C. Wainwright Neutral → Buy $7
May-06-19Upgrade Cowen Market Perform → Outperform
Mar-19-19Downgrade JP Morgan Neutral → Underweight
Mar-05-19Upgrade Morgan Stanley Underweight → Equal-Weight
Mar-04-19Downgrade SVB Leerink Outperform → Mkt Perform
Mar-04-19Downgrade H.C. Wainwright Buy → Neutral $18 → $3.50
Mar-01-19Downgrade Piper Jaffray Overweight → Neutral $13 → $2.50
Mar-01-19Downgrade Jefferies Buy → Hold
Sep-07-18Initiated Piper Jaffray Overweight
Feb-08-18Resumed RBC Capital Mkts Outperform $12
Jan-31-18Initiated H.C. Wainwright Buy $18
Jul-06-17Upgrade RBC Capital Mkts Sector Perform → Outperform $5 → $12
Apr-19-17Upgrade Leerink Partners Mkt Perform → Outperform
Apr-29-16Downgrade RBC Capital Mkts Outperform → Sector Perform $18 → $7
Jul-23-21 03:00PM  
Jul-15-21 04:01PM  
Jul-13-21 08:38AM  
Jul-01-21 04:30PM  
Jun-10-21 02:09AM  
Jun-09-21 11:30AM  
Jun-01-21 04:30PM  
May-20-21 04:30PM  
May-19-21 05:00PM  
May-10-21 12:00PM  
May-03-21 04:30PM  
Apr-26-21 04:01PM  
Apr-20-21 10:13AM  
Apr-16-21 04:41AM  
Apr-10-21 08:30AM  
Apr-01-21 04:30PM  
Mar-14-21 11:30AM  
Mar-01-21 04:30PM  
Feb-24-21 04:30PM  
Feb-14-21 11:25PM  
Feb-13-21 03:51AM  
Feb-12-21 11:30AM  
Feb-11-21 04:30PM  
Feb-05-21 12:30PM  
Feb-01-21 04:30PM  
Jan-29-21 04:01PM  
Jan-04-21 04:30PM  
Dec-30-20 04:30PM  
Dec-26-20 03:58AM  
Dec-16-20 03:20PM  
Dec-06-20 11:30AM  
Dec-05-20 03:01PM  
Dec-01-20 04:30PM  
Nov-30-20 04:30PM  
Nov-18-20 04:30PM  
Nov-11-20 06:33AM  
Nov-10-20 06:23AM  
Nov-09-20 09:56AM  
Nov-06-20 12:30PM  
Nov-05-20 10:10AM  
Nov-04-20 04:30PM  
Nov-02-20 04:30PM  
Oct-30-20 12:30PM  
Oct-29-20 10:58AM  
Oct-22-20 04:01PM  
Oct-20-20 10:56AM  
Oct-19-20 08:45AM  
Oct-12-20 01:26PM  
Oct-06-20 12:57PM  
Oct-05-20 09:52AM  
Oct-01-20 04:30PM  
Sep-17-20 03:01AM  
Sep-14-20 12:20PM  
Sep-02-20 04:30PM  
Sep-01-20 04:30PM  
Aug-30-20 11:30AM  
Aug-04-20 11:14AM  
Aug-03-20 04:30PM  
Jul-31-20 07:03PM  
Jul-29-20 04:30PM  
Jul-27-20 01:08PM  
Jul-24-20 12:30PM  
Jul-22-20 08:00AM  
Jul-20-20 07:00AM  
Jul-16-20 04:01PM  
Jul-14-20 05:31PM  
Jun-23-20 09:42PM  
Jun-22-20 09:01AM  
Jun-03-20 08:00AM  
Jun-02-20 08:00AM  
Jun-01-20 08:00AM  
May-31-20 11:30AM  
May-29-20 08:01AM  
May-20-20 10:04PM  
May-19-20 04:08PM  
May-15-20 12:01AM  
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, Inc. ImmunoGen, Inc. has collaborations with Roche; Amgen/Oxford BioTherapeutics; sanofi-aventis U. S. LLC; Biotest AG; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Fusion Pharmaceuticals Inc.; Debiopharm International SA; Jazz Pharmaceuticals Ireland Limited; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FOSTER DAVID GV.P.-Fin., Prin. Acctg. Off.Dec 31Sale6.3811,05270,51237,912Jan 04 05:32 PM